" class="no-js "lang="en-US"> Korro Bio and Genevant Sciences Enter Collaboration Agreement
Saturday, February 24, 2024

Korro Bio and Genevant Sciences Enter into Collaboration Agreement to Develop RNA Editing Therapeutic for Alpha-1 Antitrypsin Deficiency

Korro Bio, a leading RNA editing company focused on the discovery and development of novel genetic medicines, and Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust and expansive lipid nanoparticle (LNP) patent portfolio, today announced that they have entered into an agreement to combine Korro’s powerful RNA editing platform with Genevant’s industry-leading LNP technology to develop a differentiated therapeutic option for patients with Alpha-1 Antitrypsin Deficiency (AATD). Terms of the agreement were not disclosed.

“At Korro, we are developing a novel class of genetic medicines by combining our editing technology with fit-for-purpose delivery modalities. For patients with Alpha-1 Antitrypsin Deficiency, a genetic disease with high unmet medical need, we endeavor to provide a therapeutic option that returns the level of circulating protein to within the normal range,” said Ram Aiyar, Ph.D., MBA, Chief Executive Officer and President of Korro Bio. “Genevant’s expertise in the development of LNPs for clinical applications, coupled with our titratable and transient RNA editing therapies to address both liver and lung manifestations, position us well to deliver a best-in-class therapeutic for patients with AATD.”

“The challenge of delivering RNA payloads safely and effectively to specific tissues has historically been a major obstacle to unlocking the broad therapeutic potential of RNA-based medicines. As leaders in the field, the key role that innovative LNP technology can play in overcoming this challenge has been a longtime focus of Genevant scientists,” said Pete Lutwyche, Ph.D., President and Chief Executive Officer of Genevant Sciences. “We are delighted to collaborate with Korro to pursue a much-needed new treatment option for AATD patients.”

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more